The Levonorgestrel Intrauterine System is an Effective Treatment in Women with Abnormal Uterine Bleeding and Anticoagulant Therapy

George A. Vilos, MD*, Valentin Tureanu, MD, Meivys Garcia, MD, and Basim Abu-Rafea, MD

From St. Joseph’s Health Care, Department of Obstetrics and Gynecology, The University of Western Ontario, London, Ontario, Canada (all authors), and King Khalid, University Hospital, King Saud University, Riyadh, Saudi Arabia (Drs. Vilos and Abu-Rafea).

ABSTRACT
Objective: To evaluate the efficacy of levonorgestrel intrauterine systems (LNG-IUS) in obese women with AUB on anticoagulant therapy.

Design: Prospective observational case series (Canadian Task Force Classification II-3).

Setting: University affiliated teaching hospital.

Patients: Premenopausal women on Warfarin therapy.

Interventions: From January 2002 through January 2007, 10 women were identified from the senior author’s clinical practice (G.A.V.). After clinical assessment, including Papanicolaou smear, endometrial biopsy, and pelvic sonography, the LNG-IUS was placed to treat their AUB.

Measurements and Main Results: The median and range of age, parity, and body mass index were 45 years (34-49), 1 (0-4), and 38 kg/m² (26-52), respectively. All women were receiving warfarin therapy (4-12.5 mg/d) for previous venous thromboembolism. Some patients had additional comorbid conditions and were at high risk for traditional medical or surgical therapies. After placement of the LNG-IUS, all women reported menstrual reduction at 3 and 6 months. By 12 months, 1 woman with large fibroids expelled the LNG-IUS and was treated with transfemoral uterine artery embolization. Two women had amenorrhea, and 7 had hypomenorrhea. At 2 to 5 years, 1 woman expelled the LNG-IUS and hysterectomy indicated extensive adenomyosis in a 195-g uterus, and 1 woman had hysteroscopic endometrial ablation, 4 were menopausal, 2 had amenorrhea, and 1 had hypomenorrhea. In the 5 women with uterine fibroids measuring 4.2 to 147 cm³, the fibroids were reduced in volume by approximately 75% in 2, were no longer detectable in 1, were subsequently shown to be adenomyoma in 1, and required uterine artery embolization in 1.

Conclusion: In properly assessed and selected obese, premenopausal women with AUB receiving warfarin therapy and at high risk for traditional therapies, the LNG-IUS was an effective treatment in 70% of patients. Journal of Minimally Invasive Gynecology (2009) 16, 480–484 © 2009 AAGL. All rights reserved.

Keywords: LNG-IUS; Mirena; Menorrhagia; Warfarin; Thromboprophylaxis; Anticoagulant

Abnormal uterine bleeding (AUB), defined as change in any or a combination of frequency, duration or amount of bleeding is experienced by approximately 20% to 30% of premenopausal women [1,2]. In general, AUB is a common debilitating condition that results in reduced hemoglobin, adversely affects quality of life, and is associated with significant use of health care resources. The prevalence of AUB increases with age and peaks just before menopause in accordance with changes in steroidogenesis and serum sex hormones or lack of ovulation and serum progesterone [1,2].

In general, the menstrual cycle and amount of menstrual blood loss (MBL) are regulated by cyclic ovarian response to extraneous stimuli and production of estrogen and progesterone. AUB then can be modulated by partial or complete suppression of ovarian steroidogenesis with a variety of agents including combined oral contraceptives, progestins, androgens (danazol) or gonadotropin-releasing hormone agonists [1,2]. In the presence of intrauterine polyps, found in 25% to 35%, and leiomyomas, found in 15% to 30% of
women with AUB [3], effective treatments include hysteroscopic surgery or hysterectomy. In the absence of intrauterine disease, medical therapies, levonorgestrel intrauterine systems (LNG-IUS), and hysteroscopic and nonhysteroscopic endometrial ablation enjoy certain degrees of popularity in accordance with personal experience, training, expertise, and bias [1].

Among the general population of women with AUB, gynecologists occasionally encounter women with morbid conditions and ailments that may contribute to AUB in conjunction with age and hormonal, metabolic, and body mass index (BMI) changes. Such cases may include neuromuscular or bleeding disorders, cerebrovascular accidents, and thromboembolic events that may require prolonged thromboprophylaxis with anticoagulant agents. Under such circumstances, traditional therapies may be contraindicated, ineffective, refused, difficult, or quite risky to administer or perform.

In this study we report our experience with 10 women with AUB, and various comorbidities and conditions, all of which required continuous warfarin therapy, treated with LNG-IUS (Mirena; Bayer Shering Pharma AG, Berlin, Germany). Review of these patient’s records was approved by our university ethics committee (HSREB 13849 E).

**Measurements and Main Results**

From January 2002 through January 2007, we identified 10 women with AUB requiring thromboprophylaxis from the senior author’s clinical practice (G.A.V.) at a university-affiliated teaching hospital. The median for age, parity and BMI were 45 years, 1 child (range 0-4), and 38 kg/m², respectively. LNG-IUS (Mirena; Bayer Shering Pharma AG, Berlin, Germany). Review of these patient’s records was approved by our university ethics committee (HSREB 13849 E).

Traditionally, premenopausal healthy women with AUB from benign causes are managed quite effectively with a variety of treatments including oral, transdermal, or injectable medications, intrauterine hormone-releasing systems, and surgical interventions including hysteroscopic and nonhysteroscopic procedures or hysterectomy [1]. However, gynecologists occasionally are faced with women experiencing AUB with multiple health disorders and ailments in which most of the above traditional therapies are contraindicated or quite risky to administer.

In this study, the senior author (G.A.V.) was referred 10 women with AUB, and a variety of comorbidities including obesity, all of whom required thromboprophylaxis for previous thromboembolic events. Under these conditions, estrogens are contraindicated because they increase the risk of thromboembolism, injectable agents cause injection site bleeding and hematomas, and surgical treatments require temporary discontinuation or alteration of the anticoagulants. Therefore the choices for contraception and treatment options for women with AUB on anticoagulant therapy are very limited. Under such circumstances, oral progestins or LNG-IUS may be the least risky choices of therapy, but data on their use and efficacy remain quite scanty.

LNG-IUS consists of a polyethylene, barium-coated frame (32 × 32 mm) to make it radiopaque with a containing reservoir (52 mg) around its vertical stem [4]. The system initially releases levonorgestrel approximately 20 μg/d via a drug-controlling membrane, decreasing to approximately half of that by 5 years and to less than 10 μg/d from 5 to 7 years. The average release within the first 5 years is approximately 14 μg/d. Interestingly, clinical observations indicate that the efficacy of the LNG-IUS may diminish after the third year of placement for noncontraceptive uses (personal observations). LNG is absorbed from the uterine cavity very...
<table>
<thead>
<tr>
<th>Date</th>
<th>Age (Yrs)/ Parity</th>
<th>BMI kg/m²</th>
<th>Comorbidities</th>
<th>Pre-LNG-IUS Endometrial Biopsy</th>
<th>Clinical Outcomes (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/2002</td>
<td>47/4</td>
<td>28</td>
<td>DVT/PE Diabetes, MS Nephropathy</td>
<td>Proliferative</td>
<td>Hypomen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02/2003</td>
<td>48/3</td>
<td>37</td>
<td>DVT, Asthma Hypertension</td>
<td>Secretory</td>
<td>Hypomen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01/2004</td>
<td>42/1</td>
<td>26</td>
<td>DVT, Stroke Atrial fibrillation</td>
<td>Proliferative</td>
<td>Hypomen</td>
</tr>
<tr>
<td>02/2004</td>
<td>45/0</td>
<td>52</td>
<td>DVT, PCOS Fib. 38 cm³</td>
<td>Secretory</td>
<td>Hypomen</td>
</tr>
<tr>
<td>11/2004</td>
<td>49/1</td>
<td>38.1</td>
<td>DVT Fib. 12 cm³</td>
<td>Proliferative</td>
<td>Hypomen</td>
</tr>
<tr>
<td>07/2004</td>
<td>42/3</td>
<td>32.4</td>
<td>DVT/PE, MS</td>
<td>Proliferative</td>
<td>Hypomen</td>
</tr>
<tr>
<td>09/2005</td>
<td>41/0</td>
<td>48.5</td>
<td>DVT Depression</td>
<td>Proliferative</td>
<td>Hypomen</td>
</tr>
<tr>
<td>07/2005</td>
<td>34/1</td>
<td>41</td>
<td>DVT/PE ? Fib. 31 cm³</td>
<td>SEH</td>
<td>Hypomen</td>
</tr>
<tr>
<td>11/2005</td>
<td>45/3</td>
<td>36.6</td>
<td>DVT, Stroke Fib. 1.147 cm³</td>
<td>Proliferative</td>
<td>Hypomen</td>
</tr>
<tr>
<td>01/2007</td>
<td>47/1</td>
<td>39</td>
<td>DVT, Hypertension Fib. 4.2 cm³</td>
<td>Secretory</td>
<td>Hypomen</td>
</tr>
</tbody>
</table>

MS = Multiple sclerosis; SEH/CEH = simple/complex endometrial hyperplasia; DVT/PE = deep vein thrombosis/pulmonary embolism; HEA = hysteroscopic endometrial ablation; UAE = uterine artery embolization; Fib. = fibroid; Ameno = amenorrhea; Hypomen = hypomenorrhea.
The effects of LNG-IUS in women with menorrhagia has been reviewed from both cohort and randomized studies. In general, after placement of the LNG-IUS in women with menorrhagia, MBL was reduced by 79% to 97%, with patient satisfaction and continuation rates being 72% to 94% and 65% to 88%, respectively [7-12]. On the basis of the above evidence and on the limited treatment options, in our group of 10 women we elected to use the LNG-IUS after obtaining informed consent. A literature search revealed 1 case report of apparent interaction between warfarin and levonorgestrel. A 35-year-old woman was taking warfarin 7 mg daily. After 2 doses of levonorgestrel 0.75 mg given 12 hours apart for emergency contraception, the woman’s international normalized ratio rose from 2.1 to 8.1 in 3 days [13]. Current evidence suggests that the risk of thromboembolism is not increased in patients using levonorgestrel containing oral contraceptives [14]; however, there is no evidence to support the same in women who already had a thromboembolic event and are currently on thromboprophylaxis.

Association of menstrual bleeding and anticoagulant therapy has been reported in a small number of women. Van Eijkeren et al [15] measured MBL in 6 premenopausal women with various congenital or acquired bleeding disorders and in 11 women using oral anticoagulant therapy. The mean MBL, by alkaline hematin method, was 98 mL (9-239 mL) in women receiving anticoagulant therapy. Five (45%) had menorrhagia (MBL > 80 mL). Of the remaining 6 women, 2 had blood losses in the high normal range (60-80 mL). The authors concluded that oral anticoagulants increase MBL [15].

Kadir and Chi [16] in a review article reported that 9 of 11 (82%) women with bleeding disorders on anticoagulant therapy had menorrhagia ( pictorial blood loss assessment chart score > 100). Five women had development of intermenstrual bleeding, and 6 reported adverse effects on their quality of life during menstruation after the start of their anticoagulant therapy [16]. Because the prevalence of menorrhagia in the general population is 20% to 30%, the above studies indicate that bleeding disorders and anticoagulant therapy significantly increase the risk of AUB up to 80%.

The efficacy and use of the LNG-IUS in anticoagulated women with bleeding disorders has been reported in small studies. Pisoni et al [17] treated 16 women with menorrhagia associated with warfarin with the LNG-IUS. The LNG-IUS treatment was associated with a reduction of MBL in 87% of women, 4 (25%) of whom became amenorrheic, and 75% were very satisfied or satisfied with their treatment. In a follow-up study, the same authors reported on 17 women with menorrhagia on warfarin therapy. MBL was reduced in 10 (58.8%) women, with 4 (23.5%) reporting amenorrhea, no change in MBL in 1 (5.9%), increase in MBL in 2 (11.8%), and 2 did not remember. Twelve (70.6%) women were either very satisfied or satisfied with the LNG-IUS therapy [18].

Shaedel et al [19] reported on 2 women with hemostatic disorders on warfarin with the LNG-IUS. The LNG-IUS was removed 7 days after placement in 1 woman because of abdominal pain and 1 month later in the other because she had development of transverse sinus thrombosis. Nineteen of 28 (68%) women with hemostatic disorders (not on anticoagulants) experienced improvement of menstrual bleeding with the LNG-IUS [19].

Finally, Lukes et al [20] reported on 7 premenopausal women with hemostatic disorders and AUB treated with the LNG-IUS. Four women were using anticoagulants, 3 warfarin and 2 aspirin. A reduction of BML and improved quality of life was reported by 5 (71%) women [20].

Based on the above limited data, Kadir and Chi [16] in their review article concluded that the LNG-IUS is a safe and attractive option for women with hemostatic disorders, which may obviate the need for surgical interventions in these women. Their review, however, did not include any women without bleeding disorder and previous thromboembolism requiring current anticoagulants.

To our knowledge, this is the first report of women with AUB, without apparent hemostatic disorders requiring thromboprophylaxis treated with the LNG-IUS. As the table indicates, all women had comorbid conditions that may or may not have contributed to their AUB and MBL. One patient with insulin-dependent diabetes had multiple sclerosis and end-stage nephropathy. After placement of LNG-IUS, the insulin requirements did not change. A randomized trial demonstrated that the LNG-IUS had no adverse effect on glucose metabolism in diabetic women at either 6 weeks or 6 months [21].

All of our patients were overweight (BMI > 25 kg/m²). Eight were obese (BMI > 30 kg/m²), and 6 were morbidly obese (BMI > 35 kg/m²). As a rule, obesity is associated with many chronic diseases, as well as clinical conditions including venous thromboembolism, diabetes, hypertension, and menstrual disorders including uterine neoplasia [22]. Obesity currently is reaching epidemic proportions in the developed world. In 1999 to 2002, 62% of U.S. women aged 20 years or older were overweight (BMI > 25 kg/m²), and 30% were obese (BMI < 30%/m²) [22]. Under the circumstances, health care providers will encounter more and more women with similar conditions and ailments to those of our present study. Our experience therefore with this small group of patients, indicating that 7 of 10 women (70%) were effectively and safely treated with the LNG-IUS, may be of considerable benefit and value to both patients and therapists.

References


